التفاصيل البيبلوغرافية
العنوان: |
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial |
المؤلفون: |
Kosiborod, Mikhail N *, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Buenconsejo, Joan, Langkilde, Anna Maria, Ambery, Philip, Tang, Fengming, Gosch, Kensey, Windsor, Sheryl L, Akin, Emily E, Soares, Ronaldo V P, Moia, Diogo D F, Aboudara, Matthew, Hoffmann Filho, Conrado Roberto, Feitosa, Audes D M, Fonseca, Alberto, Garla, Vishnu, Gordon, Robert A, Javaheri, Ali, Jaeger, Cristiano P, Leaes, Paulo E, Nassif, Michael, Pursley, Michael, Silveira, Fabio Serra, Barroso, Weimar Kunz Sebba, Lazcano Soto, José Roberto, Nigro Maia, Lilia, Berwanger, Otavio |
المصدر: |
In The Lancet Diabetes & Endocrinology September 2021 9(9):586-594 |
قاعدة البيانات: |
ScienceDirect |